← All trials
NCT05599516
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 4, 2022
- Primary completion
- Oct 31, 2023
- Completion date
- Dec 31, 2023
- First posted
- Oct 31, 2022
- Last posted
- Nov 10, 2022
- Enrollment
- 16000
- Arms / groups
- 5 / —
- Source
- AACT · ctgov ingestion
Sponsors
- National Vaccine and Serum Institute, ChinaLead sponsor
- China National Biotec Group Co., LtdCollaborator
- China National Biotec Group Co., LtdCollaborator
- Beijing Tiantan Bio Co., LtdCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.